Form D · Pharmaceuticals
Clementia Pharmaceuticals Inc.
Dorval, A8 · CIK 0001647320
Offering snapshot reported Jul 7, 2015 · SEC filing
- Reported sold
- $60M Offering amount: $60M
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 22, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 7, 2015 | Initial | $59,999,141 | No comparison | 16 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $2.15M
- Finders' fees
- $0
- Form D file number
- 021-243197
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Leerink Partners LLC | 39011 |
Source: Form D, filed Jul 7, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David P. Bonita | Director |
| Clarissa Desjardins | Director, Executive |
| Eric Grinstead | Executive |
| Donna Roy Grogan | Executive |
| Robert Heft | Director |
| Allan Mandelzys | Director |
| Francois Nader | Director |
| Jeffrey Packman | Executive |
| Jean Francois Pariseau | Director, Executive |
| Michael Singer | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1375 Trans Canada Highway Suite 200
Dorval, A8, H9P 2W8
Dorval, A8, H9P 2W8